Gut microbiota and the paradox of cancer immunotherapy

Theofilos Poutahidis1,2, Markus Kleinewietfeld3,4,5 and Susan E. Erdman1*

1 Division of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, MA, USA
2 Laboratory of Pathology, Faculty of Veterinary Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
3 Departments of Neurology and Immunobiology, Yale School of Medicine, New Haven, CT, USA
4 Broad Institute, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA
5 Faculty of Medicine, Dresden University of Technology (TUD), Dresden, Germany

It is recently shown that beneficial environmental microbes stimulate integrated immune and neuroendocrine factors throughout the body, consequently modulating regulatory T-lymphocyte phenotypes, maintaining systemic immune balance, and determining the fate of preneoplastic lesions toward regression while sustaining whole body good health. Stimulated by a gut microbiota-centric systemic homeostasis hypothesis, we set out to explore the influence of the gut microbiome to explain the paradoxical roles of regulatory T-lymphocytes in cancer development and growth. This paradigm shift places cancer prevention and treatment into a new broader context of holobiont engineering to cultivate a tumor-suppressive macroenvironment.

Keywords: tumor macroenvironment, regulatory T-cells, cancer immunotherapy, inflammation and cancer, probiotic bacteria

INTRODUCTION

The neoplastic process is characterized by overwhelming complexity. Cancer is comprised of a genetically unstable population of cells that proliferate at an extraordinarily high rate. Millions of cancer deaths each year make it obvious that the battle against cancer is asymmetric, with humankind often being the weaker element (1). To date, cancer research efforts directly confront malignancy by targeting properties of individual cancer cells. In 2000, Hanahan and Weinberg described that most of the research on origins of cells that proliferate at an extraordinarily high rate. Millions of cancer deaths each year make it obvious that the battle against cancer had just contributed toward "adding further layers of complexity to a scientific literature that is already complex almost beyond measure" (2).

In the same landmark paper, however, the authors were optimistic enough to predict groundbreaking upcoming advances in the conceptual rather than the technical level (3). They were proven right. One such advancement was the increased awareness for the importance of the tumor microenvironment in the etiopathogenesis of neoplasia (3, 4). We now know that initially transformed cells are much less autonomous in their growth than previously thought (5, 6). Among the microenvironment elements, immune cells and factors have emerged as fundamental players (4–6). Accumulating evidence suggests that tumor-associated inflammatory cell accumulation, whether overt or smoldering, could be viewed as a tumor-promoting event (7–9). These inflammatory responses enhance mutagenesis by oxidative DNA damage and shape the tumor stroma in favor of cancer cell survival and expansion (6, 10, 11).

Will this knowledge base in the field of inflammation, immunity, and cancer lead to new, highly effective, and biologically safe cancer immunotherapy modalities? We assert that the outcome will depend upon the philosophy and the strategic goals that will dominate the bench-to-bedside research. We propose that research in this field should focus upon stimulating systemic innate immune balance and adaptive immune resiliency, making the mammalian host more powerful to resist its cancer challenger. One possible approach utilizes gut microbiota or microbial antigens to stimulate beneficial immune cells. On the other hand, existing immunotherapy aims to selectively interrupt immune factors to better recognize and exterminate cancer cells (12–17), an approach that may ultimately lead to host instability. To further explain this point of view, we will refer to the recently discovered paradoxical roles of regulatory T-cells (T_{REG}) in cancer (10, 14).

T_{REG} ARE CENTRAL IN PRESERVING SYSTEMIC IMMUNE HOMEOSTASIS AND GOOD HEALTH

FOXP3+ CD4+ CD25+ CD127low T_{REG} are dominant cellular elements of the professional suppressor arm of the immune system and are important for orchestrating the control of peripheral immunological tolerance (18). The transcription factor FOXP3 is a fundamental regulator of T_{REG} function in rodents and humans, and so far the most reliable phenotypic indicator of their identity. Recent studies on human T_{REG} subpopulations, however, revealed that low but discernible levels of FOXP3 expression could be detected in non-suppressive T_{REG} or even in activated effector T-cells. It is probable that this finding reflects the inherent plasticity of T_{REG}; FOXP3+ cells co-expressing effector T-cell phenotypic markers or cytokines may be in stages of a progressive, epigenetically regulated, phenotypical, and functional shift process (14, 16, 19–22), ultimately favorable for healthful recovery of the host after environmental challenges. The role of T_{REG} is central in preserving immune system homeostasis for health and the balance of beneficial inflammatory responses during infections while minimizing collateral tissue damage. In cancer, however, roles of T_{REG} are traditionally considered to be negative (14–16, 23).

T_{REG} GATHER NEAR TUMORS AND FAVOR CANCER SURVIVAL

A large body of data suggest that T_{REG} gather near tumors and suppress the anti-tumor inflammatory response, thus favoring cancer...
cell survival. To this end, tumor-associated T\textsubscript{REG} are thought as a major impediment of anti-tumor vaccines (13–16, 23). Clinical and experimental data suggest that tumor-associated T\textsubscript{REG} recognize both self and neoantigens expressed by tumor cells, counteracting antigen-specific effector T-cell responses. Consequently, immunotherapy strategies based on the vaccination with tumor-associated antigens fail to evoke an effective response against cancer cells due to the activation and expansion of tumor antigen-specific T\textsubscript{REG} (14–16). This potential interplay of T\textsubscript{REG} within tumors has been reviewed in detail elsewhere (12–16), and has led to the proposal of several anti-T\textsubscript{REG} regimes for cancer immunotherapy. These regimens aim to deplete T\textsubscript{REG}, inhibit their suppressive function, prevent their homing into tumor sites, or block their differentiation/proliferation (12–16).

Several of these T\textsubscript{REG}-targeting modalities have already been tested in the clinic, with mixed results (13, 16). Blocking T\textsubscript{REG} function by depleting the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) appears promising (24), due to the depletion of T\textsubscript{REG} from tumor tissues (25, 26). However, a similar regimen could lead to an opposite effect with the accumulation of T\textsubscript{REG} and CD8\textsuperscript{+} T-cells in tumors (27, 28). A phase III study of melanoma patients using a gp100 peptide vaccine with interleukin (IL)-2 administration led to equally promising results with discovery of T\textsubscript{REG} expansion in responding patients (29).

**GUT MICROBIOTA INDUCE POTENT T\textsubscript{REG} WITH SYSTEMIC ANTI-NEOPLASTIC PROPERTIES**

As the results of these trials are anticipated, the literature reveals contradictory evidence. Indeed, the studies associating high densities of tumor-associated cells expressing T\textsubscript{REG} markers including FOXP3 with a poor prognosis in several types of human cancers are now challenged by similar studies on the very same types of cancer showing the opposite outcome (30–34). The different CD8\textsuperscript{+}:T\textsubscript{REG} ratios and the presence of FOXP3\textsuperscript{+} cell subsets of undetermined identity in the tumor microenvironment have been proposed as probable explanations (16). Indeed, data from animal models show under certain conditions of microbial priming that T\textsubscript{REG} not only protect but also alter the tumor microenvironment to induce remission of already established intestinal, mammary, and prostate cancers (35–41). The hypothesis that the composition of the different subsets of FOXP3\textsuperscript{+}, which may include effector Foxp3\textsuperscript{+} cells, is intriguing (16). Indeed, it was previously shown that IFN-γ levels were increased during T\textsubscript{REG}-mediated tumor regression in mice (37). Further, feeding of probiotic microbes to mice induces systemic oxytocin secretion that shifts immunity toward IFN-γ and CD25 for improved wound healing capacity and systemic good health (42). A question subsequently arising is whether gut microbiota may be engineered to harness an anti-neoplastic FOXP3\textsuperscript{+} cell milieu (5, 10, 41).

**GUT-CENTRIC HYPOTHESIS: PRIOR EXPOSURES TO MICROBES EXPLAIN BENEFICIAL ROLES OF T\textsubscript{REG}**

Stimulated by a gut-centric systemic homeostasis hypothesis, we set out to explore and explain the paradoxical roles of T\textsubscript{REG} in cancer using several different mouse models of cancer and adoptive cell transfer methodologies (10). We found that T\textsubscript{REG} may suppress, promote, or have no effect in carcinogenesis depending upon their timing and prior exposure to gut bacterial antigens and presence of IL-10 (35–39, 41, 43, 44). Under some conditions, adoptive transfer of T\textsubscript{REG} rapidly led to apoptosis of emerging tumor cells (37, 45). Using as a model organism an opportunistic pathogen, Helicobacter hepaticus, commonly residing in the lower bowel of mice, we have shown in Rag2-deficient mice (otherwise lacking lymphocytes) that gut microbiota modulate inflammatory bowel disease and inflammation-associated colon cancer, a cancer process inhibited by properly functioning IL-10-dependent T\textsubscript{REG} (35, 36). Subsequently, by introducing H. hepaticus into the large bowel flora of mice lacking the APC tumor suppressor gene (Apc\textsuperscript{Min/+}), we found that intestinal polyposis was greatly enhanced by bacteria and subsequently suppressed by immune-competent T\textsubscript{REG}. Furthermore, adenomas of infected Apc\textsuperscript{Min/+} mice progressed into adenocarcinoma, a transition atypical of polyps of aged-matched uninfected controls (38, 41). Interestingly, Apc\textsuperscript{Min/+} mice having H. hepaticus in their gut flora were prone to develop cancer in tissues distant from intestine, such as prostate and the mammary glands (40, 41, 43, 46, 47). H. hepaticus-induced tumorigenic events were inhibited by supplementation with T\textsubscript{REG} from immune-competent wild type donor mice.

A potent treatment to counteract these local and systemic H. hepaticus-induced tumorigenic events was supplementation with T\textsubscript{REG} in an IL-10-dependent manner (10, 36, 38–40, 44, 46, 48). Purified T\textsubscript{REG} exhibited greatest anti-cancer potency when taken from donor mice previously colonized with H. hepaticus. By contrast, T\textsubscript{REG} taken from donor mice without prior H. hepaticus exposure were ineffective, and in some cases actually enhanced tumorigenesis (10). Based on these results, we theorize that the tumor microenvironment is subject to systemic inflammatory events arising from environmental exposures in the gastrointestinal tract (Figure 1). This microbe-inducible pro-inflammatory condition contributes to tumor trophic signaling. Interestingly, bacterial antigen triggered IL-10-dependent activities in the GITract impart sustained protection from the aforementioned events, resulting in immune cell recruitment, including T\textsubscript{REG}, which, by being more potent in their anti-inflammatory roles, work locally and systemically to suppress sepsis, myeloid precursor mobilization, and inflammatory signaling important in extra-intestinal cancer evolution (10, 43). These systemic events comprise the tumor microenvironment.

The roles of intestinal microflora in promoting cancer development within the bowel have been well established (35, 49–52). Linking gut microbial flora and local and systemic effects that promote (38) or suppress (45) tumors throughout the body, expands this paradigm in a challenging manner. Recent findings show that gut flora imbalances considerably undermine the response to both immune (53, 54) and non-immune chemotherapeutic regimens, such as cisplatin and oxaliplatin (53).

**A WEAKENED T\textsubscript{REG} FEEDBACK LOOP UNIFIES AUTOIMMUNE DISEASES AND CANCER**

These gut microbe-centric findings in mice are consistent with the “hygiene hypothesis,” according to which insufficient microbial exposures earlier in life predispose to allergies, autoimmunity disorders, and uncontrollable inflammation-associated pathologies later in life. We have shown that the basic principles of this
unstable resting peripheral T REG IL-10 and T notypic plasticity (10). Hygienic individuals with a weakened anti-neoplastic T REG homeostasis and reinforce a protective anti-inflammatory, microbiota-triggered IL-10, which works to maintain immune system risk for cancer and counteract established tumors depends upon this phenomenon (10, 41, 55). The ability of T REG neoplastic disease as well, and that T REG hypothesis may apply not only to auto-immunity, but also to sleeping immune system status may determine the risk of developing cancer, while nearly everyone bears dysplastic and early neoplastic lesions throughout their body (56).

Figure 1 | Gut bacteria–host crosstalk is continuous and reciprocal in the cancer macroenvironment. Beneficial microbes trigger IL-10-mediated GI-tract immune and neuronal networks that lower systemic inflammatory tone and up-regulate hypothalamic–hypophyseal targets, including oxytocin, constituting a gut–systemic immunity-endocrine-axis. In this way, microbiota stimulate CD4 + lymphocytes including regulatory T cells (T REG) that suppress, promote, or have no effect in carcinogenesis depending upon their timing and prior exposure to gut bacterial antigens and presence of interleukin (IL)-10. This places neoplastic development and growth into a new broader context of the holobiont (comprised of the mammalian host plus resident microbes) and the cancer macroenvironment, highlighting microbes that may be engineered for sustained good health.

BENEFICIAL SYSTEMIC EFFECTS OF GUT MICROBES ARE TRANSPLECTABLE VIA FOXP3+ T REG INTO NAÏVE HOSTS

Adoptive cell transfer models offer mechanistic insight as these beneficial effects were isolated to bacteria-primed T REG (42, 47, 57–59). In fact, healthful phenotypes were entirely reproducible in naïve recipient mice by the adoptive transfer of highly purified T REG derived from probiotic-fed cell donors (42, 57, 59). These results suggest gut microbe-induced crosstalk with the host in a continuous and reciprocal manner. The fate of preneoplastic and neoplastic lesions arising in epithelia throughout the body depends upon this macroenvironment at the whole organism level. Consequently, the tumor macroenvironment is defined as the “holobiont,” i.e., the mammalian organism plus the microbial symbionts it bears. The T REG population is a central player of the tumor macroenvironment connecting gut bacteria with reproductive fitness, youthful phenotypes, and anti-neoplastic properties.

MICROBIAL ENGINEERING OFFERS NEW STRATEGIES FOR PUBLIC HEALTH

Taken together, microbial engineering strategies using food-grade bacteria highlight alternative directions in cancer immunotherapy. Modulating beneficial T REG via diet is a biologically safe and efficient approach, originating from genetic programs that have been shaped during the millions of years of co-evolution of mammals with their gut bacteria symbionts. These attributes remain largely inactive in individuals with a modern lifestyle, Westernized dietary habits, and stringent hygiene practices. Awakening these latent T REG-mediated capabilities may provide an alternative avenue to reduce cancer risk at a population level for public health. The perspectives presented here should be considered as an alternative paradigm – not only for fighting cancer – but also for promoting overall good health and longevity.

www.frontiersin.org

April 2014 | Volume 5 | Article 157 | 3

Poutahidis et al. Gut bacteria modulate the tumor macroenvironment
AUTHOR CONTRIBUTIONS
Theofilos Poutahidis, Markus Kleineieweltfeld, and Susan E. Erdman wrote the paper.

ACKNOWLEDGMENTS
This work was supported by National Institutes of Health grants P30-ES002109 (pilot project award to Susan E. Erdman), U01 CA164337 (to Susan E. Erdman), and RO1CA108854 (to Susan E. Erdman).

REFERENCES
1. Stewart BW, Wild CP editors. World Cancer Report 2014. Lyon: Codex (2014).

2. Hanahan D, Weinberg RA. Hallmarks of cancer. Cell (2000) 100:57-70. doi:10.1016/S0092-8674(00)81683-9

3. Bisell MJ, Radiisky D. Putting tumours in context. Nat Rev Cancer (2001) 1:46-54. doi:10.1038/35094059

4. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell (2011) 144:646-74. doi:10.1016/j.cell.2011.02.013

5. Erdman S, Poutahidis T. Roles for inflammation and regulatory T cells in colon cancer. Tossal Pathol (2010) 38:76-87. doi:10.1177/10192399351410

6. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell (2012) 21:39-22. doi:10.1016/j.ccr.2012.02.022

7. Ballwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet (2001) 357:539-45. doi:10.1016/S0140-6736(01)04966-0

8. Ballwill F, Coussens LM. Cancer: an inflammatory link. Nature (2004) 431:405-6. doi:10.1038/431405a

9. Ballwill F. Cancer and the chemokine network. Nat Rev Cancer (2004) 4:540-50. doi:10.1038/nrc1388

10. Erdman SE, Poutahidis T. Cancer inflammation and regulatory T cells. Int J Cancer (2010) 127:768-79. doi:10.1002/ijc.25430

11. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis (2009) 30:1073-81. doi:10.1039/b906416d

12. Curiel TJ. Regulatory T cells and treatment of cancer. Curr Opin Immunol (2008) 20:241-6. doi:10.1016/j.coi.2008.04.008

13. Whiteside TL. What are regulatory T cells (Treg) regulating in cancer and why? Semin Cancer Biol (2012) 22:327-34. doi:10.1016/j.semcancer.2012.03.004

14. Mougiakakos D, Choudhury A, Lladser A, Kiessling R, Johansson CC. Regulation of T cell tolerance without regulatory T cell development. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression at the single-cell level. Immunology (2009) 103:103-107. doi:10.1111/j.1365-2567.2008.03161.x

15. Colombo MP, Piccone S. Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer (2007) 7:880-7. doi:10.1038/nrc2250

16. Nishikawa H, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Curr Opin Immunol (2014) 27C:1-7. doi:10.1016/j.coi.2013.12.005

17. Gajewski TF, Fuertes MB, Woo SR. Innate immune sensing of cancer: clues from an identified role for type I IFNs. Cancer Immunol Immunother (2012) 61:1343-7. doi:10.1007/s00262-012-1305-6

18. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell (2008) 135:787-807. doi:10.1016/j.cell.2008.05.009

19. Roncador G, Brown PJ, De Jong RA, Hoogeboom BN, Ten Hoor KA, Hollema H, et al. Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother (2009) 58:449-59. doi:10.1007/s00262-008-0583-5

20. Wilke CM, Wu K, Zhao E, Wang G, Zou W. Prognostic significance of regulatory T cells in tumor. Int J Cancer (2010) 127:748-58. doi:10.1002/ijc.25464

21. Erdman SE, Poutahidis T, Tomczak M, Rogers AB, Cormier K, Plank B, et al. CD4+CD25+ regulatory T lymphocytes inhibit microbially induced colon cancer in Rag2-deficient mice. Am J Pathol (2003) 162:691-702. doi:10.1016/S0002-9440(03)63863-1

22. Erdman SE, Rao VP, Poutahidis T, Hihir MM, Ge Z, Feng Y, et al. CD4+CD25+ regulatory lymphocytes require interleukin 10 to inhibit colon cancer growth in mice. Cancer Res (2003) 63:6940-50.

23. Erdman SE, Sohn JJ, Rao VP, Namibi PR, Ge Z, Fox JG, et al. CD4+CD25+ regulatory lymphocytes induce regression of intestinal tumors in ApcMin+/- mice. Cancer Res (2005) 65:3998-4004. doi:10.1158/0008-5472.CAN-04-3104

24. Rao VP, Poutahidis T, Ge Z, Namibi PR, Boussahmain C, Wang YY, et al. Intrahepatic immune inflammatory response against enteric bacteria Helicobacter hepaticus induces mammary adenocarcinoma in mice. Cancer Res (2006) 66:7395-400. doi:10.1158/0008-5472.CAN-06-1558

25. Poutahidis T, Haigis KM, Rao VP, Namibi PR, Taylor CL, Ge Z, et al. Rapid reversal of interleukin-6-dependent epithelial invasion in a mouse model of microbially induced colon carcinoma. Carcinogenesis (2007) 28:2614-23. doi:10.1093/carcin/bgm180

26. Poutahidis T, Rao VP, Olipitin W, Taylor CL, Jackson EA, Levkovic T, et al. CD4+ lymphocytes mediate prostate cancer progression in mice. Int J Cancer (2009) 125:868-78. doi:10.1002/ijc.24452

27. Erdman SE, Rao VP, Olipitin W, Taylor CL, Jackson EA, Levkovic T, et al. Unifying roles for regulatory T cells and inflammation in cancer. Int J Cancer (2010) 126:6521-65. doi:10.1002/ijc.24923

28. Poutahidis T, Kleineieweltfeld M, Smillie C, Levkovic T, Ferrotta A, Bhide S, et al. Microbial reprogramming inhibits western diet-associated obesity. PLoS One (2013) 8:e68596. doi:10.1371/journal.pone.0068596

29. Rao VP, Poutahidis T, Fox JG, Erdman SE. Breast cancer: should gastrointestinal bacteria be on our radar screen? Cancer Res (2007) 67:847-50. doi:10.1158/0008-5472.CAN-06-3468
44. Erdman SE, Rao VP, Poutahidis T, Rogers AB, Taylor CL, Jackson EA, et al. Nitric oxide and TNF-alpha trigger colonic inflammation and carcinogenesis in Helicobacter hepaticus-infected, Rag2-deficient mice. Proc Natl Acad Sci U S A (2009) 106:1027–32. doi:10.1073/pnas.0812347106

45. Lakritz JR, Poutahidis T, Levkovich T, Varian BJ, Ibrahim YM, Chatzigiagkos A, et al. Beneficial bacteria stimulate host immune cells to counteract dietary and genetic predisposition to mammary cancer in mice. Int J Cancer (2013). doi:10.1002/ijc.28702

46. Rao VP, Poutahidis T, Ge Z, Nambiar PR, Horwitz BH, Fox JG, et al. Proinflammatory CD4+ CD45RB(hi) lymphocytes promote mammary and intestinal carcinogenesis in ApC[Min(+) ] mice. Cancer Res (2006) 66:57–61. doi:10.1158/0008-5472.CAN-05-3445

47. Poutahidis T, Cappelle K, Levkovich T, Lee CW, Doulberis M, Ge Z, et al. Pathogenic intestinal bacteria enhance prostate cancer development via systemic activation of immune cells in mice. PLoS One (2013) 8:e73933. doi:10.1371/journal.pone.0073933

48. Houghton J, Li H, Fan X, Liu Y, Liu JH, Rao VP, et al. Mutations in bone marrow-derived stromal stem cells unmask latent malignancy. Stem Cells Dev (2010) 19:1153–66. doi:10.1089/scd.2009.0439

49. Terzic J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology (2010) 138(2101–2114):e5. doi:10.1053/j.gastro.2010.01.058

50. Zhu Y, Michelle Luo T, Jobin C, Young HA. Gut microbiota and probiotics in colon tumorigenesis. Cancer Lett (2011) 309:119–27. doi:10.1016/j.canlet.2011.06.004

51. Arthur JC, Perez-Chanona E, Muhlbauer M, Tomkovich S, Uronis JM, Fan TJ, et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science (2012) 338:120–3. doi:10.1126/science.1224820

52. Song X, Gao H, Lin Y, Yao Y, Zhu S, Wang J, et al. Alterations in the microbiota drive interleukin-17C production from intestinal epithelial cells to promote tumorigenesis. Immunity (2014) 40:140–52. doi:10.1016/j.immuni.2013.11.018

53. Iida N, Drutz A, Stewart CA, Smith L, Bouladoux N, Weingarten RA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science (2013) 342:967–70. doi:10.1126/science.1240527

54. Viaud S, Saccheri F, Mignot G, Yamazaki T, Dailliere R, Hannani D, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science (2013) 342:971–6. doi:10.1126/science.1240537

55. Rook GA, Dalgleish A. Infection, immunoregulation, and cancer. Immunol Rev (2011) 240:141–59. doi:10.1111/j.1600-065X.2010.00987.x

56. Folkman J, Kalluri R. Cancer without disease. Nature (2004) 427:787. doi:10.1038/427787a

57. Poutahidis T, Kearney SM, Levkovich T, Qi P, Varian BJ, Lakritz JR, et al. Microbial symbionts accelerate wound healing via the neuropeptide hormone oxytocin. PLoS One (2013) 8:e78898. doi:10.1371/journal.pone.0078898

58. Levkovich T, Poutahidis T, Smillie C, Varian BJ, Ibrahim YM, Lakritz JR, et al. Probiotic bacteria induce a ‘glow of health.’ PLoS One (2013) 8:e53867. doi:10.1371/journal.pone.0053867

59. Poutahidis T, Erdman S. Probiotic “glow of health”: more than skin deep. Benef Microbes (2014) 5:109–19. doi:10.3920/BM2013.0042

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 11 February 2014; accepted: 25 March 2014; published online: 07 April 2014.
Citation: Poutahidis T, Kleinewietfeld M and Erdman SE (2014) Gut microbiota and the paradox of cancer immunotherapy. Front. Immunol. 5:157. doi:10.3389/fimmu.2014.00157
This article was submitted to Tumor Immunity, a section of the journal Frontiers in Immunology.
Copyright © 2014 Poutahidis, Kleinewietfeld and Erdman. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.